Insights

Market Focus Arcutis operates in the immuno-dermatology segment with a focus on developing innovative dermatological therapies, creating opportunities to engage with dermatologists and healthcare providers seeking advanced solutions for inflammatory skin conditions.

Product Accessibility The launch of the Zoryve Direct Program demonstrates Arcutis's commitment to improving patient access through copay assistance and support programs, presenting a sales opportunity to partner with healthcare providers and pharmacies for broader product distribution.

Financial Growth With revenues between fifty and one hundred million dollars, Arcutis shows strong market traction, indicating significant sales potential in expanding their product portfolio and entering new dermatology markets.

Leadership and Growth Recent strategic hires and executive promotions underscore Arcutis’s growth trajectory and management focus, offering sales teams opportunities to collaborate with a rapidly evolving company investing heavily in innovation.

Industry Engagement Active participation in key industry events and conferences suggests Arcutis's openness to partnerships and collaborations, providing multiple channels for business development activities targeting dermatology specialists and healthcare organizations.

Similar companies to Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT)

Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) Tech Stack

Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) uses 8 technology products and services including Linkedin Insight Tag, Zoom Rooms, Cloudflare, and more. Explore Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT)'s tech stack below.

  • Linkedin Insight Tag
    Analytics
  • Zoom Rooms
    Communication And Collaboration
  • Cloudflare
    Content Management System
  • Salesforce
    Customer Relationship Management
  • TeamViewer
    Customer Service
  • oEmbed
    Dev Tools
  • Apple Business Manager
    Enterprise Mobility Management
  • Fortinet
    Network Hardware

Media & News

Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT)'s Email Address Formats

Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) uses at least 1 format(s):
Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) Email FormatsExamplePercentage
FLast@arcutis.comJDoe@arcutis.com
94%
Last@arcutis.comDoe@arcutis.com
4%
First-Last@arcutis.comJohn-Doe@arcutis.com
1%
FiLast@arcutis.comJoDoe@arcutis.com
1%

Frequently Asked Questions

What is Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT)'s official website and social media links?

Minus sign iconPlus sign icon
Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT)'s official website is arcutis.com and has social profiles on LinkedInCrunchbase.

What is Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT)'s SIC code NAICS code?

Minus sign iconPlus sign icon
Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT)'s SIC code is 8733 - Noncommercial Research Organizations NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) have currently?

Minus sign iconPlus sign icon
As of December 2025, Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) has approximately 381 employees across 2 continents, including North AmericaEurope. Key team members include Chief Technology Officer: B. D.Chief Compliance & Privacy Officer: C. B.Chief Medical Officer: P. B.. Explore Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT)'s employee directory with LeadIQ.

What industry does Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) belong to?

Minus sign iconPlus sign icon
Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) operates in the Biotechnology Research industry.

What technology does Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) use?

Minus sign iconPlus sign icon
Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT)'s tech stack includes Linkedin Insight TagZoom RoomsCloudflareSalesforceTeamVieweroEmbedApple Business ManagerFortinet.

What is Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT)'s email format?

Minus sign iconPlus sign icon
Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT)'s email format typically follows the pattern of FLast@arcutis.com. Find more Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) email formats with LeadIQ.

When was Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) founded?

Minus sign iconPlus sign icon
Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) was founded in 2016.

Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT)

Biotechnology ResearchCalifornia, United States201-500 Employees

Arcutis (Nasdaq: ARQT) was founded in 2016 to address significant unmet needs in medical dermatology. The company is an early commercial stage biopharmaceutical company focused on developing and commercializing best-in-class products.

Our strategy is to exploit recent innovations in inflammation and immunology to bring the best molecules to bear against validated physiologic targets known to treat dermatological diseases and disorders. 

Our management team has extensive expertise in the development and commercialization of medical dermatology products, having held key leadership roles at a number of leading dermatology companies and, collectively, has successfully developed more than 50 FDA-approved products. We believe that by leveraging our team’s unique experience and demonstrated expertise to identify, develop and commercialize best-in-class molecules against validated targets, we will be able to develop differentiated products in less time, at lower cost, and at substantially lower risk than other approaches.

Arcutis' combination of vision, unmet medical need, experienced management and strategic approach has attracted support from leading investors in the life sciences sector.

Section iconCompany Overview

SIC Code
8733 - Noncommercial Research Organizations
NAICS Code
541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Founded
2016
Employees
201-500

Section iconFunding & Financials

  • $50M$100M

    Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT)'s revenue is estimated to be in the range of $50M$100M

Section iconFunding & Financials

  • $50M$100M

    Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT)'s revenue is estimated to be in the range of $50M$100M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.